Hardy John
UCL Institute of Neurology and Dementia Research Institute, London, UK.
J Neurochem. 2025 Jul;169(7):e70148. doi: 10.1111/jnc.70148.
Alzheimer research has been driven by genetic findings: from the 1990s until about 2005, by the identification of amyloid precursor protein (APP) and presenilin (PSEN) mutations, leading to the formulation of the amyloid hypothesis, and then from ~2007 by genome-wide studies which have led to the increasing appreciation of the importance of microglial insufficiency in the disease pathogenesis. These genome findings have led not only to key mechanistic insights but also to progress in the use of genetic data to predict those at high risk of the disease so that earlier treatment becomes more practical. In this review I will outline these developments and attempts to synthesise the findings into a coherent single view of the disease.
从20世纪90年代到2005年左右,通过鉴定淀粉样前体蛋白(APP)和早老素(PSEN)突变,形成了淀粉样蛋白假说,然后从2007年左右开始,全基因组研究使人们越来越认识到小胶质细胞功能不足在疾病发病机制中的重要性。这些基因组研究结果不仅带来了关键的机制性见解,也推动了利用遗传数据预测疾病高危人群方面的进展,从而使早期治疗变得更具可行性。在这篇综述中,我将概述这些进展,并尝试将研究结果综合成一个关于该疾病的连贯统一观点。